Dataset from A Single-Arm Phase II Study in Japan to Assess the Efficacy and Safety of Aflibercept Administered Every Two Weeks in Combination With FOLFIRI in Patients With Metastatic Colorectal Cancer Who Progressed During or Following an Oxaliplatin-Based Regimen

Primary Objective:To assess efficacy aflibercept + 5-fluorouracil (5-FU)/levofolinate/irinotecan (FOLFIRI) by objective response rate (ORR).Secondary Objective:To assess the following:* safety profile;* progression free survival (PFS);* overall survival (OS);* pharmacokinetics (PK);* immunogenicity.